Monitoring the Inter-Dose Interval for Long-acting Injectable Antipsychotics: pilot for the MIDILIA study

What is the study about?
This study is looking into how long acting injectable antipsychotics changes between injections. After receiving a dose, it takes a few days before the drug is fully released. Over the following days and weeks, the level of medication reduces. The aim of the study is to see if this reduction leads to a worsening of symptoms.

Who can take part?
Adults prescribed and compliant with long-acting injectable antipsychotic (LIA) medication, engaged in treatment with in an inpatient or outpatient setting. Participants should have received a minimum of four administrations of their LIA medication consistent in drug type and dose prior to the research period.

What is involved?
The research will involve two meetings with a Trust doctor. The first meeting will be a few days after the depot dose, which will be when the level of medication will be highest. The second meeting will be on the same day, or the day before the next depot dose At each encounter, the researcher will take a blood sample and talk with you to determine how your mental health is at that time. This will be a questionnaire called the Positive and Negative Syndrome Scale, or PANSS which is widely used in research.

How can people get involved?
Eligible participants will be invited to take part by their care team during routine appointments. If you are a clinician and would like to know more about the study, please contact the study lead Dr James O’Neill Midilia.lypft@nhs.net